When was Eligo Bioscience founded?

Eligo Bioscience was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Eligo Bioscience located?

Eligo Bioscience is headquartered in Paris, France.

Who is the current CEO of Eligo Bioscience?

Xavier Duportet of Eligo Bioscience. They have also founded 1 company and are an angel investors in 1 startup.

Is Eligo Bioscience a funded company?

Eligo Bioscience is a funded company, having raised a total of $52.3M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 08, 2015.

When was the latest funding round of Eligo Bioscience?

Eligo Bioscience's latest funding was a $***** Grant (prize money) round on May 13, 2025, with participation from 1 investor. Its primary sector is Genomics. Globally, the Genomics sector has seen $501M in funding in 2026 to date.

What is the annual revenue of Eligo Bioscience?

Annual revenue of Eligo Bioscience is €1.62M as on Dec 31, 2021.

Where does Eligo Bioscience rank among its competitors?

Eligo Bioscience ranks 16th amongst 115 active competitors, of which 59 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Precision BioSciences, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of Eligo Bioscience?

Eligo Bioscience's top competitors include eGenesis, Mammoth and Metagenomi. Among them, Precision BioSciences secured the most recent funding round in March, 2026.

Eligo Bioscience - 2026 Company Profile, Team, Funding, Competitors & Financials

Eligo Bioscience is a series B company based in Paris (France), founded in 2014 by Xavier Duportet. It operates as a Developer of in vivo gene editing technology for microbiome modulation. Eligo Bioscience has raised $52.3M in funding from investors like Khosla Ventures, Seventure Partners and Sanofi Ventures. The company has 115 active competitors, including 59 funded and 12 that have exited. Its top competitors include companies like eGenesis, Mammoth and Metagenomi.

Company Details

Developer of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system.

Website: eligo.bio
Social
Email ID: *****@eligo-bioscience.com

Key Metrics

Founded Year

2014

Location

Paris, France

Stage

Series B

Total Funding

$52.3M in 7 rounds

Latest Funding Round

Grant (prize money), May 13, 2025, $*****

Investors

Khosla Ventures & 6 more

Ranked

16^th among 115 active competitors

Annual Revenue

€1.62M as on Dec 31, 2021

Similar Companies

eGenesis & 129 more

View Eligo Bioscience's full profile

Eligo Bioscience is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Eligo Bioscience CIN: 802255372 , France, Active	Feb 06, 2014	$1.92M (As on Dec 31, 2021)	-	-

Eligo Bioscience has raised a total funding of $52.3M over 7 rounds. Its first funding round was on Jul 08, 2015. Its latest funding round was a Grant (prize money) round on May 13, 2025 for $*****. 1 investor participated in its latest round. Eligo Bioscience has 7 institutional investors.

Here is the list of recent funding rounds of Eligo Bioscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2025	2317875	Grant (prize money)	2585376	5777181	5304574	7133280
Nov 05, 2023	2619902	Series B	1276807	6441732	2911116	Bpifrance & 2 more
Mar 31, 2022	2158835	Grant (prize money)	7691934	3359951	2990552	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Eligo Bioscience's funding rounds and investors

The founders of Eligo Bioscience is Xavier Duportet. Xavier Duportet is the CEO of Eligo Bioscience.

Here are the details of Eligo Bioscience's key team members:

Xavier Duportet: Co-Founder & CEO of Eligo Bioscience. They are also an angel investor in 1 startup.
Contact Info: 1 email address

View details of Eligo Bioscience's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eligo Bioscience include eGenesis, Mammoth and Metagenomi. Here is the list of Top 10 competitors of Eligo Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Monashee Investment Management, Biomatics Capital ... & 30 others	65/100
2nd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Mayfield & 34 others	65/100
3rd	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
4th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	ADIA, March Capital & 22 others	64/100
5th	Precision BioSciences 2006, Durham (United States), Public	Developer of gene editing therapies to treat rare genetic diseases	$136M	ArrowMark Partners, VenBio & 29 others	64/100
6th	Scribe Therapeutics 2018, Alameda (United States), Series B	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 6 others	61/100
7th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	Redmile Group, F-Prime Capital & 10 others	61/100
8th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, F-Prime Capital & 16 others	60/100
9th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Viking Global Investors, Tencent & 13 others	60/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Eclipse, Decheng Capital	60/100
16th	Eligo Bioscience 2014, Paris (France), Series B	Developer of in vivo gene editing technology for microbiome modulation	$52.3M	Sanofi Ventures, Khosla Ventures & 5 others	55/100